Liver transplantation for hepatocellular carcinoma: Extension of indications based on molecular markers
Myron Schwartz(Icahn School of Medicine at Mount Sinai), Josep M. Llovet(Icahn School of Medicine at Mount Sinai), John A. Martignetti(Cancer Clinic), S. D. Finkelstein(University of Pittsburgh), J. Wallis Marsh(West Virginia University), Igor Dvorchik(University of Pittsburgh), Sasan Roayaie(White Plains Hospital), Maria Isabel Fiel(Icahn School of Medicine at Mount Sinai)
Cited by 84
Related Papers
Hepatocellular carcinoma
|Nature Reviews Disease Primers|2021|6.6k
Clinical Management of Hepatocellular Carcinoma. Conclusions of the Barcelona-2000 EASL Conference
|Journal of Hepatology|2001|4.1k
Hepatocellular carcinoma
|Nature Reviews Disease Primers|2016|2.7k
Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis
|The Lancet Oncology|2008|2k
Design and Endpoints of Clinical Trials in Hepatocellular Carcinoma
|JNCI Journal of the National Cancer Institute|2008|1.7k